Monte Rosa Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited results are compared with the three months ended March 31, 2023. Monte Rosa is a pre-commercial biotechnology company developing molecular glue degraders (MGDs) using its QuEEN platform.
Financial and operating results
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Collaboration revenue | $1.1 million | None |
| Research and development expense | $27.0 million | $26.8 million |
| General and administrative expense | $9.0 million | $7.5 million |
| Operating loss | $34.9 million | $34.3 million |
| Net loss | $32.0 million | $32.0 million |
| Net loss per share, basic and diluted | $0.53 | $0.65 |
| Net cash used in operating activities | $38.2 million | $23.4 million |
Cash, cash equivalents and marketable securities totaled $192.9 million at March 31, 2024; including restricted cash, total cash and investments were $197.8 million. Total current assets were $199.0 million and current liabilities were $41.3 million. The company reported no credit facility or committed capital sources. Operating lease liabilities totaled $45.2 million; no other debt is identified in the filing.
Operating expenses rose 5% year over year, driven principally by higher G&A costs. R&D expense was nearly flat. The net loss was modestly lower, supported by collaboration revenue and higher other income, including a $0.6 million foreign-exchange gain. Operating cash use increased by $14.8 million year over year, partly reflecting working-capital changes. No product revenue was reported.
Collaboration, outlook and risks
- Under its Roche collaboration, Monte Rosa recognized $1.1 million of revenue in Q1 from a $50 million non-refundable upfront payment received in November 2023. At March 31, $48.9 million remained deferred. Roche had not exercised options for additional targets. Potential milestones and royalties are contingent and are not assured.
- Management expects cash, cash equivalents and marketable securities to fund operating expenses and capital requirements for at least 12 months from issuance of the interim financial statements. It expects continued operating losses and negative operating cash flow, with additional financing needed for future research and development.
- Development priorities include the MRT-2359 clinical study, preparing MRT-6160 for clinical entry, and progressing preclinical programs including NEK7 and CDK2. On May 9, 2024, the company announced a new discovery program targeting CCNE1-amplified tumors.
- Key uncertainties include clinical and preclinical outcomes, regulatory and manufacturing execution, the timing and cost of development, and the availability and terms of future financing. Failure to secure funding could require delaying, reducing or ending programs. Global economic and political disruption may also affect operations and capital markets.
- The company reported no litigation or established litigation contingency reserve as of March 31, 2024, and no material changes to contractual commitments during the quarter. Management concluded disclosure controls were effective at a reasonable-assurance level.
Investor verification points
- Confirm the reported cash runway assumptions and expected pace of cash use, particularly given Q1 operating cash outflow of $38.2 million.
- Track clinical and regulatory progress for MRT-2359 and MRT-6160, and updates on MRT-8102 and other pipeline programs.
- Monitor Roche option exercises, collaboration revenue recognition and any achievement of contingent milestones.
- Review potential dilution: 10.0 million pre-funded warrants remained unexercised at quarter-end but are included in the weighted-average share count used for earnings per share; 11.7 million stock options were outstanding.